Specifically, prostate cancer organoids cultured in Arg-Glu-Asp-Val (REDV)-functionalized hydrogels showed reduced actin symmetry under enhancer of zeste homolog 2 (EZH2) inhibition, illustrating ECM-dependent drug responses [458]. The gene discussed is EZH2; the disease is prostate cancer.